Title |
Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy
|
---|---|
Published in |
BMC Biology, October 2014
|
DOI | 10.1186/s12915-014-0082-4 |
Pubmed ID | |
Authors |
Alba Luengo, Lucas B Sullivan, Matthew G Vander Heiden |
Abstract |
Metformin has been a first-line treatment for type II diabetes mellitus for decades and is the most widely prescribed antidiabetic drug. Retrospective studies have found that metformin treatment is associated with both reduced cancer diagnoses and cancer-related deaths. Despite the prevalence of metformin use in the clinic, its molecular mechanism of action remains controversial. In a recent issue of Cancer & Metabolism, Andrzejewski et al. present evidence that metformin acts directly on mitochondria to inhibit complex I and limits the ability of cancer cells to cope with energetic stress. Here, we discuss evidence that supports the role of metformin as a cancer therapeutic. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 33% |
Spain | 1 | 17% |
Singapore | 1 | 17% |
Unknown | 2 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 50% |
Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Scientists | 1 | 17% |
Science communicators (journalists, bloggers, editors) | 1 | 17% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Chile | 1 | <1% |
South Africa | 1 | <1% |
Czechia | 1 | <1% |
China | 1 | <1% |
United States | 1 | <1% |
Unknown | 126 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 26 | 20% |
Researcher | 19 | 15% |
Student > Master | 18 | 14% |
Student > Bachelor | 15 | 11% |
Student > Doctoral Student | 6 | 5% |
Other | 20 | 15% |
Unknown | 27 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 32 | 24% |
Medicine and Dentistry | 29 | 22% |
Agricultural and Biological Sciences | 29 | 22% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 5% |
Environmental Science | 2 | 2% |
Other | 7 | 5% |
Unknown | 26 | 20% |